Cybin Inc

CYBN

6.070USD

+0.120+2.02%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

Cybin Inc's Score

Industry at a Glance

Industry Ranking

112 / 407

Overall Ranking

228 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

84.833

Target Price

+1325.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cybin Inc Highlights

StrengthsRisks

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -1.34, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.89M shares, decreasing 88.50% quarter-over-quarter.

The company's current financial score is 7.45, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.45

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.91

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.91

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 7.33, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.34, which is -4.28% below the recent high of -1.29 and -9974.77% above the recent low of -135.26.

Score

Industry at a Glance

Previous score

7.33

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/407

No Data

The company’s current earnings forecast score is 8.29, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Cybin Inc is 88.00, with a high of 150.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.29

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 5.89, which is lower than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 7.48 and the support level at 5.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.81

Change

0.08

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nivorozhkin (Alex)

5.25M

+5.65%

Tang Capital Management, LLC

1.83M

--

Point72 Asset Management, L.P.

Star Investors

1.61M

+21.12%

Global X Investments Canada Inc.

1.34M

-13.73%

Tziras (George)

1.29M

--

Deep Track Capital LP

1.53M

--

Bartlone (Aaron Frank)

901.07K

+28.53%

Rosalind Advisors, Inc.

810.92K

--

Acorn Capital Advisors, LLC

734.39K

--

Fahel (Gabriel)

405.35K

+0.54%



1

2



The company’s current risk assessment score is 4.21, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Cybin Inc

CYBN

6.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment